Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) is a once-weekly injection developed to treat type 2 diabetes, but it has become widely prescribed off-label for weight loss due to remarkable results in clinical studies. The active ingredient semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and blood sugar. PlexusDx provides access to compounded semaglutide injections through licensed 503A pharmacies, offering the same active ingredient at substantially lower cost without the need for insurance.
How Ozempic Got Used for Weight Loss Despite Its Original Purpose
Ozempic was initially developed and approved by the FDA exclusively for managing type 2 diabetes. The medication became a weight loss tool when physicians noticed patients experienced significant appetite suppression and weight reduction as a side effect during diabetes treatment. This off-label use gained momentum after observational data showed people lost an average of 10-15% of their body weight over 68 weeks in real-world settings.
The injectable form of semaglutide requires a prescription from a licensed healthcare provider, regardless of whether it is being used for diabetes or weight management. Insurance companies often deny coverage for off-label weight loss uses, forcing patients to pay out-of-pocket or seek alternatives like compounded versions. PlexusDx connects patients with licensed prescribers who can evaluate whether GLP-1 therapy is appropriate for individual health profiles.
Clinical Evidence Behind Semaglutide for Weight Loss
The STEP trials, a series of randomized controlled studies, provided robust evidence that semaglutide drives meaningful weight loss in people without diabetes. Participants receiving semaglutide 2.4 mg weekly achieved an average weight loss of 16-18% of baseline body weight over 68 weeks, compared to 2-3% in placebo groups. These results formed the basis for Wegovy, the FDA-approved weight loss version of semaglutide, though it carries a significantly higher retail price than brand-name Ozempic.
Semaglutide works by binding to GLP-1 receptors in the brain, signaling fullness and reducing hunger hormones like ghrelin. It also slows gastric emptying, meaning food stays in your stomach longer, promoting sustained satiety. The medication improves blood sugar control even in non-diabetic individuals, which contributes to metabolic benefits beyond appetite reduction.
Why Compounded Semaglutide Offers an Accessible Alternative
Brand-name Ozempic costs $900-$1,200 per month without insurance, and Wegovy can exceed $1,500 monthly at retail pharmacies. PlexusDx offers compounded semaglutide injections starting at $149 per month through licensed 503A compounding pharmacies, making the same active ingredient available to far more patients. Compounded medications contain identical active pharmaceutical ingredients as their brand-name counterparts but are prepared by state-licensed pharmacies rather than manufactured by pharmaceutical corporations.
All PlexusDx compounded medications are prepared exclusively through licensed 503A compounding pharmacies, which are regulated by state pharmacy boards and the FDA. Your dose may need to go up as your body adjusts to therapy, but your price remains flat—no hidden increases tied to higher doses. PlexusDx serves all 50 states and accepts HSA and FSA payments, removing insurance as a barrier to access.
Personalization Through Genetic Testing and Peptide Mapping
Not every person responds identically to GLP-1 therapy, which is why genetic variation matters in treatment selection. PlexusDx offers the Precision Peptide Genetic Test, an add-on available after your first month of treatment, which analyzes key genetic variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These variants influence how your body responds to appetite-regulating peptides and metabolic pathways, helping PlexusDx map 14 pathways, 49 peptides, and 150+ genetic insights specific to your physiology.
Genetic predispositions can predict whether you may respond better to semaglutide alone, tirzepatide (a dual GIP/GLP-1 agonist), or combination protocols. Some patients carry variants that enhance GLP-1 receptor sensitivity, while others may benefit from the additional GIP pathway activation offered by tirzepatide. Personalized genetic insights help prescribers optimize your starting dose and anticipated trajectory, increasing the likelihood of sustained weight loss and reduced side effects.
Safety Profile and Common Side Effects of GLP-1 Therapy
Semaglutide is well-tolerated in most patients, but gastrointestinal side effects are common during the first 4-8 weeks of treatment. Nausea, vomiting, diarrhea, and constipation occur in 20-50% of users, though these typically diminish as the body adapts. Slower dose escalation—starting at lower injection doses and increasing gradually every 1-2 weeks—significantly reduces the severity of GI symptoms.
Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury, though these occur at very low rates in clinical trials. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use semaglutide. A PlexusDx prescriber will review your complete medical history and contraindications before initiating therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic actually approved by the FDA for weight loss?
No, Ozempic is FDA-approved only for type 2 diabetes. Doctors prescribe it off-label for weight loss based on clinical evidence of its appetite-suppressing effects. PlexusDx offers compounded semaglutide—the same active ingredient—which is legally prescribed off-label for weight management under physician supervision.
What is the difference between Ozempic, Wegovy, and compounded semaglutide?
Ozempic and Wegovy both contain semaglutide manufactured by Novo Nordisk but are marketed for different indications at vastly different prices. Compounded semaglutide contains identical active pharmaceutical ingredients prepared by licensed 503A pharmacies and costs significantly less—starting at $149 monthly with PlexusDx—without requiring insurance approval.
How much does PlexusDx compounded semaglutide cost compared to brand-name options?
PlexusDx compounded semaglutide injections start at $149 per month with pricing that remains flat regardless of dose increases. Brand-name Ozempic typically costs $900-$1,200 monthly, while Wegovy exceeds $1,500. PlexusDx also accepts HSA and FSA payments and serves all 50 states without insurance requirements.
Are compounded medications as safe as brand-name versions?
Yes. PlexusDx uses only licensed 503A compounding pharmacies, which are state-regulated and FDA-monitored for quality and sterility. Compounded medications contain identical active pharmaceutical ingredients as their brand-name equivalents—the difference is cost and manufacturing location, not safety or efficacy.
How can genetic testing help predict my response to semaglutide?
PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence your body's response to appetite regulation and metabolic pathways. This testing, available as a $99 add-on after your first treatment month, helps your prescriber optimize your therapy and predict whether you may respond better to semaglutide alone or combination protocols.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Lose Weight on a Low Dose of Ozempic?
Can I Take Ozempic and Metformin Together for Comprehensive Health?